Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 89 recruiting now early-phase tilt #39 of 28,707 conditions

Head and Neck Cancer: early-phase trial registry

89 of 260 indexed Head and Neck Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #39 of 28,707 conditions by registered trial count.

260 US clinical trials · 89 currently recruiting · #39 of 28,707 conditions by registered trial count

Head and Neck Cancer: 260 US clinical trials tracked, 89 recruiting.

Head and Neck Cancer is the subject of 260 registered US clinical trials on ClinicalTrials.gov, 89 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 137 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 19 of these trials.

Enrollment posture brief

Registry condition head-and-neck-cancer

OPEN 89 | RECR 34% | LATE 13 | EARLY 137 | RANK #39 | SPON 19

Nearest open-share peer: Recurrent Malignant Solid Neoplasm (34% recruiting · 38 trials)

Opioid Use Disorder60.5%Aging47.9%Post Traumatic Stress Disord41.5%Head and Neck Cancer (this)34%Melanoma33.1%
Open-enrollment share among volume-matched conditions near Head and Neck Cancer

Head and Neck Cancer lists 89 open slots (34% of 260 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Head and Neck Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Head and Neck Cancer is recruiting below its size-band peers.

    89 of 260 indexed trials (34.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Head and Neck Cancer trials is spread across many organizations.

    M.D. Anderson Cancer Center accounts for 19 of 260 trials (7.3%). 124 distinct sponsors appear on at least one study for this condition label.

  3. Most Head and Neck Cancer trials plan to enrol fewer than 100 people.

    Median target enrolment is 53 among the 251 trials that report a genuine target (sentinel values excluded). 165 of those (65.7%) plan for fewer than 100 participants.

  4. Head and Neck Cancer research is mostly interventional.

    213 interventional and 47 observational studies make up this index (81.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 163Phase 274Phase 311Phase 42

Open and recent trials

260 total, page 6 of 6

COMPLETED Phase 1 1 participants

Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)

University of Miami

NCT00077051

COMPLETED Phase 2

Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer

Eastern Cooperative Oncology Group

NCT00040807

COMPLETED Phase 2

Oxaliplatin in Treating Patients With Advanced Head and Neck Cancer

Ohio State University Comprehensive Cancer Center

NCT00005035

COMPLETED Phase 2

Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer

National Cancer Institute (NCI)

NCT00004089

COMPLETED Phase 2

Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer

Memorial Sloan Kettering Cancer Center

NCT00005814

COMPLETED Phase 3

Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer

Eastern Cooperative Oncology Group

NCT00002888

COMPLETED Phase 3

Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer

Radiation Therapy Oncology Group

NCT00006481

COMPLETED Phase 2

Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Memorial Sloan Kettering Cancer Center

NCT00003443

COMPLETED

Study of Proteins in Head and Neck Cancer Cells

Vanderbilt University Medical Center

NCT00896948

COMPLETED NA

Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer

National Cancer Institute (NCI)

NCT00019201

← Previous Page 6 of 6

Phase Distribution

PhaseTrial count
Phase 1 63
Phase 2 74
Phase 3 11
Phase 4 2

Named interventions

Most-linked intervention names on Head and Neck Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

cisplatin Drug
14 trials
Cisplatin Drug
10 trials
Carboplatin Drug
10 trials
radiation therapy Radiation
9 trials
Pembrolizumab Drug
8 trials
paclitaxel Drug
6 trials
Paclitaxel Drug
6 trials
Nivolumab Drug
6 trials

US sites by state

Facility locations filed on Head and Neck Cancer trials. A trial with sites in several states counts in each.

California 58 trials
Texas 49 trials
New York 45 trials
Florida 38 trials
Pennsylvania 32 trials
Illinois 29 trials
Tennessee 28 trials
Massachusetts 27 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Head and Neck Cancer page

260 registered trials, 89 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Head and Neck Cancer condition card totals 260 registered trials; most-linked intervention cisplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.